We are passionate and proud about our company.

We feel privileged to contribute in the important fight against serious infectious diseases – one of the biggest threats to human health.


Niels Moeller

MD, CEO and co-founder



Niels is a medical doctor from the University of Copenhagen and BA of Economics from Copenhagen Business School. He has worked as a Medical Director within the area of Companion Diagnostics for two years and prior to that as a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca for two years. Niels began this career at Servier Pharmaceuticals as Marketing Manager. Niels has been external lecturer at Copenhagen Business School on the BioBusiness and Innovation Program.


Andreas Mattsson

M. Sc., CSO and co-founder



Andreas holds a Master of Science in engineering and bioinformatics from the Danish Technological University and is currently finishing his PhD. Prior to working at Evaxion, he has worked for six years for Novo Nordisk developing in silico platforms. Over the last five years Andreas has worked on developing Evaxion’s in silico platform including EDEN Technology. Andreas is currently developing new in silico technologies, which will enable cancer vaccine discovery, speed up the vaccine discovery and develop his capabilities.


Tom Wylonis

Ph.D, Dr., Chairman of the Board



Tom is a former Global Director of McKinsey & Company where he worked in the USA and Europe from 1975-1997. While at McKinsey, Tom consulted with top management of high-tech companies (including pharmaceutical companies) on issues related to research, innovation, product development, strategy & organizational development. Tom was a leader of its innovation Practice, which included in its leadership other members such notables as Richard Foster and Clayton Christensen. Prior to working for McKinsey & Company, Tom worked at the Bell Telephone Laboratories (Bell Labs) as a Member of Technical Staff. Tom holds a Bachelor of Science degree from the Pennsylvania State University (Penn State), a Master of Science degree in Electrical Engineering/Operations Research from the Massachusetts Institute of Technology (MIT), and a Doctor of Philosophy degree in Operations Research from The New York University (NYU). Tom has been or is on the board of directors for several Danish companies – Incentive, NNE Pharmaplan, Vertic and Wizerize. More recently Tom has joined the Charleston Angel Partners as an ‘angel’ investor in four high-tech start-ups (First String Research Inc., Advanced Liquid Logic Inc., Zipit Inc., and Terressentia Inc.). He is active in educational innovation as part of his roles as Chairman of the Board of the US Foundation for the Copenhagen International School, as a mentor-instructor at MIT, as an advisor to the Chancellor or Penn State Schuylkill, as a mentor to Penn State engineering students, and as a mentor to students at the Citadel.


Lars Wegner

MD, Board Member



Lars began his career as an Medical doctor before joining Pfizer within medical affairs, marketing and sales.  In 2007, he joined Bavarian Nordic, where is currently Vice President of Commercial Affairs (sales, marketing and business development). Lars has international vaccine experience within development, sales, marketing and business development. He is currently Chairman of the Board at Byform Aps and member of the Board at Codesealer.

Roberto Prego Novo

President, Board Member



Roberto has served on the board of directors and as President, Principal Accounting Officer and Secretary of Cocrystal Pharma Inc. Roberto has served as the President of Laboratorios Elmor S.A., a Venezuelan pharmaceutical company. Roberto also served as the Vice President, Latin America, of Teva Pharmaceutical Industries Limited from 2006 to 2010 and as the Vice President, Latin America, of IVAX Corporation from 2006 to 2008. Roberto brings a wealth of experience and knowledge to the board as an executive in large pharmaceutical companies and as an investor in biotech companies.

Prof. Guido Grandi Ph.D

Guido was previously a senior manager at Novartis Vaccines and Diagnostics as well as being a Professor in Biochemistry and Biotechnology at several Italian Universities including Milan, Siena, Pisa and the University of Trento. Grandi became Head of the Molecular Biology Department of the Vaccines Division of Novartis Vaccines & Diagnostics and was soon promoted to Vice President for Research. Grandi set up the Proteomics facility at the Siena Research Center and actively promoted the use of Proteomics as a tool for vaccine identification.

Arup is the founding Director of MIT’s Institute of Medical Engineering and Science,the Ragon Institute of MIT and Professor of Chemical Engineering, Physics, and Biological Engineering at MIT. After obtaining his PhD in chemical engineering at the University of Delaware, and postdoctoral studies at the University of Minnesota he move to Berkeley. Where he rose through the ranks to serve as the Warren and Katherine Schlinger Professor of Chemistry and Biophysics. Later becoming Head of Theoretical and Computational Biology at Lawrence National Laboratory before moving to MIT in 2005.

Prof. Søren Brunak, Dr. phil., Ph.D



Associate Prof. Morten Nielsen Ph.D;

Prof. Arup K. Chakraborty Ph.D


Sabine Molleskov Pedersen

Executive Communications

email: smp@evaxion-biotech.com

Tel: +45 31 26 26 15

Ole Maaloesvej 3

2200 Copenhagen N, Denmark

© Copyright 2015 Evaxion Biotech All rights reserved